Abstract
Purpose While intermediate and late age-Related Macular Degeneration (AMD) have been widely investigated, rare studies were focused on the pathophysiologic mechanism of early AMD. Delayed rod-mediated dark adaptation (RMDA) is the first functional biomarker for incident early AMD. The status of outer retinal bands on optical coherence tomography (OCT) may be potential imaging biomarkers and the purpose is to investigate the hypothesis that the integrity of interdigitation zone (IZ) may provide insight into the health of photoreceptors and retinal pigment epithelium (RPE) in early AMD.
Methods We establish the structure-function relationship between ellipsoid zone (EZ) integrity and RMDA, and IZ integrity and RMDA in a large-scale OCT dataset from eyes with normal aging (n=237), early AMD (n=138), and intermediate AMD (n=101) by utilizing a novel deep-learning-derived algorithm with manual correction when needed to segment the EZ and IZ on OCT B-scans (57,596 B-scans), and utilizing the AdaptDx device to measure RMDA.
Results Our data demonstrates that slower RMDA is associated with less preserved EZ (r = -0.334; p<0.001) and IZ area (r = -0.591; p<0.001), and decreased IZ thickness (r = -0.434; p<0.001). These associations are not apparent when considering normal eyes alone.
Conclusions The association with IZ area and RMDA in large-scale data is biologically plausible because retinoid availability and transfer at the interface attributed to IZ is rate-limiting for RMDA. This study supports the hypothesis that the IZ integrity provides insight into the health of photoreceptors and RPE in early AMD and is a potential new imaging biomarker.
Competing Interest Statement
CAC receives research funds from Genentech/Hoffman LaRoche, Heidelberg Engineering, Regeneron, and Novartis, and consults for Apellis, Astellas, Boehringer Ingelheim, Character Biosciences, Osanni, and Annexon (outside this project). CO consults for Johnson & Johnson Vision (outside this project) and is a patent holder for the AdaptDx. SRS consults for 4DMT, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc. Apellis Pharmaceuticals, Inc. Astellas, Bayer, Healthcare Pharmaceuticals, Biogen MA, Inc., Boerhinger Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., Genentech, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals, Inc., Merck & Co., Inc, Nanoscope, Notal Vision Inc., Novartis, Optos Inc., Oxurion/Thrombogenics, Oyster Point Pharma, Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis and Vertex Pharmaceuticals Inc., lectures for Carl Zeiss Meditec, Heidelberg Engineering, Nidek Inc., Novartis Pharma, and Topcon Medical Systems Inc., and, receives grant funding from Carl Zeiss Meditec and Heidelberg Engineering (outside this project). ZJH receives research funds from Heidelberg Engineering (outside this project).
Clinical Trial
NCT04112667
Funding Statement
This work was supported by the National Eye Institute of the National Institutes of Health under Award Numbers R01EY029595 and R21EY030619, Research to Prevent Blindness, EyeSight Foundation of Alabama, and the Dorsett Davis Discovery Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) is a prospective cohort study on normal aging and early and intermediate AMD whose purpose is to validate retinal imaging biomarkers in these conditions with visual function measures (Clinicaltrials.gov identifier NCT04112667, October 7, 2019). The study was approved by the Institutional Review Board of the University of Alabama at Birmingham. All participants provided written informed consent after the nature and purpose of the study were explained. Conduct of the study followed the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
